Novel Tests

Explore our research into novel biomarker testing

Heparin-Binding EGF-Like Growth Factor (HB-EGF)

Heparin-binding EGF-like growth factor (HB-EGF) is one of several proteins that bind and activate the epidermal growth factor receptor (EGFR). Once activated, EGFR triggers signalling pathways that control cell growth, proliferation and survival. HB-EGF is widely expressed and may play important roles in the repair and regeneration of tissues throughout the body, including the skin, liver and gastrointestinal tract.

Heparin-Binding EGF-Like Growth Factor (HB-EGF)

Why Heparin-Binding EGF-Like Growth Factor (HB-EGF) matters

HB-EGF is a growth factor involved in regulating cell proliferation and tissue repair, and its expression may increase in response to tissue injury or damage. However, dysregulated HB-EGF signalling may lead to inappropriate activation of the epidermal growth factor receptor (EGFR), which has been implicated in cancer development. Elevated HB-EGF expression has been reported in some malignancies, including ovarian and breast cancers, where it may contribute to tumour growth and progression. These observations suggest that HB-EGF may have potential utility as a tumour biomarker.

Ready To Transform Your Laboratory Services?

Elevate your healthcare provider experience. Speak with us today to discuss your health service needs.

Book A Call Today Drop Us A Message

More Novel Tests

Amphiregulin

arrow_forward_ios

Transforming Growth Factor Alpha (TGF-α)

arrow_forward_ios

Dickkopf-1 (DKK-1)

arrow_forward_ios

Programmed Cell Death Protein 1 (PD-1)

arrow_forward_ios

Mesothelin

arrow_forward_ios

Soluble Receptor for Advanced Glycation End Products (sRAGE)

arrow_forward_ios

Galectin-3

arrow_forward_ios

Monomeric CRP (mCRP)

arrow_forward_ios

Interleukin-18 (IL-18)

arrow_forward_ios

Free PSA Isoforms

arrow_forward_ios

References

Chung, H. W. (2015). Clinical significance and usefulness of soluble heparin binding-epidermal growth factor in gastric cancer. World Journal of Gastroenterology, 21(7), 2080-2088.Dao, D. T. (2018). Heparin-binding epidermal growth factor-like growth factor as a critical mediator of tissue repair and regeneration. The American Journal of Pathology, 188(11), 2446-2456.Dickson, J. H. (2006). Helicobacter pylori can induce heparin-binding epidermal growth factor expression via gastrin and its receptor. Cancer Research, 66(15), 7524-7531.Farey, J. E. (2017). Decreased levels of circulating cancer-associated protein biomarkers following bariatric surgery. Obesity Surgery, 27(3), 578-585.Hikita, S. Y. (2011). Assessment of HB-EGF levels in peritoneal fluid and serum of ovarian cancer patients using ELISA. Anticancer Research, 31(7), 2553-2559.Kasai, N. K. (2012). Soluble heparin-binding EGF-like growth factor (HB-EGF) detected by newly developed immuno-PCR method is a clear-cut serological biomarker for ovarian cancer. American Journal of Translational Research, 4(4), 415-421.Kjær, I. M. (2020). Dysregulated EGFR pathway in serum in early-stage breast cancer patients: a case control study. Scientific Reports, 10(1), 6714.Matsumoto, S. K. (2002). Increased plasma HB-EGF associated with obesity and coronary artery disease. Biochemical and Biophysical Research Communications, 292(3), 781-786.Miyamoto, S. H. (2004). Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Research, 64(16), 5720-5727.Miyata, K. Y. (2017). Serum heparin-binding epidermal growth factor-like growth factor (HB-EGF) as a biomarker for primary ovarian cancer. Anticancer Research, 37(7), 3955-3960.Olsen, D. A. (2012). Increased concentrations of growth factors and activation of the EGFR system in breast cancer. Clinical Chemistry and Laboratory Medicine, 50(10), 1809-1818.Rogmans, C. F. (2022). Nectin-4 as blood-based biomarker enables detection of early ovarian cancer stages. Cancers, 14(23), 5867.Sato, S. D. (2012). A potent anti-HB-EGF monoclonal antibody inhibits cancer cell proliferation and multiple angiogenic activities of HB-EGF. PLoS One, 7(12).Shetty, P. P. (2017). Annexin A2 and its downstream IL-6 and HB-EGF as secretory biomarkers in the differential diagnosis of Her-2 negative breast cancer. Annals of Clinical Biochemistry, 54(4), 463-471.Tanaka, Y. M. (2005). Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clinical Cancer Research, 11(13), 4783-4792.Yagi, H. M. (2005). Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer. British Journal of Cancer, 92(9), 1737-1745.Yin, Y. G. (2010). Helicobacter pylori potentiates epithelial:mesenchymal transition in gastric cancer: links to soluble HB-EGF, gastrin and matrix metalloproteinase-7. Gut, 59(8), 1037-1045.Yotsumoto, F. O. (2010). HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer. International Journal of Cancer, 127(11), 2707-2717.